Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report by Clemens B. Tempfer et al.
CASE REPORT Open Access
Intraperitoneal cisplatin and doxorubicin as
maintenance chemotherapy for
unresectable ovarian cancer: a case report
Clemens B. Tempfer1*, Franziska Hartmann2, Ziad Hilal1 and Günther A. Rezniczek1
Abstract
Background: Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy.
Intraperitoneal chemotherapy may be an alternative local maintenance therapy.
Case presentation: A 75 year old woman with laparoscopically and histologically confirmed unresectable OC was
treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m2 and doxorubicin 1.5 mg/m2 over 2 years using
laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC). Objective tumor response (tumor regression
on histology, stable disease on repeated video-laparoscopy and peritoneal carcinomatosis index) was noted. No
Common Terminology Criteria for Adverse Events (CTCAE) > grade 3 were observed. EORTC QLQ-C30 quality of life
measurements were stable throughout the therapy.
Conclusions: Repeated intraperitoneal chemotherapy with cisplatin and doxorubicin applied as PIPAC may be an
effective maintenance treatment in women with primary advanced, unresectable OC.
Keywords: Ovarian cancer, Intraperitoneal chemotherapy, Maintenance, Peritoneal carcinomatosis, PIPAC, Quality of
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Background
Ovarian cancer (OC) usually presents at an advanced
stage due to the lack of efficient screening programs and
the absence of pathognomonic clinical symptoms. For
example, in a large series of 1009 women with epithelial
OC, 78% of women initially diagnosed with this disease
had Fédération Internationale des Gynécologues et
Obstétriciens (FIGO) stage III or IV disease [1]. In
women with advanced OC, the tumor typically metasta-
sizes into the abdominal cavity involving the abdominal
side walls, the small and large bowel, the mesentery, and
the diaphragm. Between 40% and 80% of these women
successfully undergo cytoreduction with no residual dis-
ease or residual disease <1 cm [2]. However, a substan-
tial proportion of patients is deemed unresectable upon
diagnostic laparoscopy or exploratory laparotomy. In
these patients, palliative chemotherapy or - alternatively -
neoadjuvant chemotherapy with three or four cycles of
carboplatin and paclitaxel followed by a second attempt at
surgery, i.e. intervention debulking, is the therapy of
choice [2, 3]. A number of cytotoxic agents have shown
activity in this situation, among them liposomal doxorubi-
cin, topotecan, gemcitabine, and trabectedin [4]. These
substances, alone or in combination, achieve a wide range
of response rates. For example, Ferrero et al. described a
response rate of 49% with gemcitabine and vinorelbine in
platinum-sensitive patients [5], whereas Burger et al.
found a response rate of 29% in a mixed resistant-sensitive
population [6]. Lower response rates are seen among
platinum-resistant patients with response rates of 25% [7],
21% [8], 11% [9], and even 3% [10] with doxorubicin and
gemcitabine, topotecan and oxaliplatin, gemcitabine and
vinorelbine, and vinorelbine in various combinations and
dosages, respectively. Regarding survival, palliative
chemotherapy regimens achieve median overall sur-
vival rates after the first, second, third, fourth, and
fifth relapse of 17.6 (95% CI 16.4–18.6), 11.3 (10.4–12.9),
8.9 (7.8–9.9), 6.2 (5.1–7.7) and 5.0 (3.8–10.4) months, re-
spectively [11].
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Women with unresectable OC are in a palliative situ-
ation and therefore, side effects of toxic chemotherapy
and quality of life become important issues when judg-
ing the pros and cons of standard treatment regimens.
Palliative systemic chemotherapy has a considerable
morbidity, especially when given as polychemotherapy
with or without targeted therapies such as bevacizumab
or olaparib. Common Terminology Criteria for Adverse
Events (CTCAE) grade 3 to 4 are seen in up to 50% of
patients [4–10]. Thus, effective and less morbid alterna-
tives to systemic palliative chemotherapy are an unmet
medical need for women with primary unresectable OC.
Pressurized intraperitoneal aerosol chemotherapy
(PIPAC) is a new form of intraperitoneal chemotherapy
taking advantage of the physical properties of gas and
pressure. PIPAC has been shown to increase the distribu-
tion and infiltration depth of intraperitoneal chemother-
apy, while at the same time reducing the chemotherapy
dose by a factor of 10 as compared with systemic intraven-
ous applications [12]. Furthermore, PIPAC can be admin-
istered repeatedly and has been shown to induce
regression of peritoneal tumor nodules with limited hep-
atic and renal toxicity [13]. In a prospective phase II trial
of women with recurrent OC, PIPAC with cisplatin and
doxorubicin achieved a clinical benefit rate of 62% accord-
ing to Response Evaluation Criteria In Solid Tumors
(RECIST) criteria and a histological tumor regression rate
of 76% [13]. In addition, PIPAC has been shown to be well
tolerated with a stabilization and even an increase of the
quality of life of patients with peritoneal carcinomatosis
(PC) from ovarian, gastric, and colon cancer [13, 14].
The documented good tolerability and positive effects
on quality of life make PIPAC a candidate for a mainten-
ance chemotherapy in women with unresectable OC. As
of yet, however, there are no data describing PIPAC as a
possible means of maintenance therapy in patients with
primary unresectable OC. Here we report the case of a
successful long-term maintenance treatment over two
years with intraperitoneal cisplatin and doxorubicin ap-
plied as PIPAC.
Case presentation
We present the case of a 75 year old woman with OC,
first diagnosed in 2014. The patient underwent diagnos-
tic laparoscopy with histologic confirmation of a high-
grade serous adenocarcinoma of the right ovary. The
tumor was not resectable due to extensive small bowel
involvement. In addition, due to her clinical condition,
the patient declined systemic chemotherapy with carbo-
platin and paclitaxel. The patient was offered local,
intraabdominal chemotherapy with cisplatin and doxo-
rubicin applied as PIPAC as an off-label procedure. The
patient provided written informed consent for this treat-
ment and for publication of this case report. We did not
obtain Ethics Committee approval, since no approval is
required for a singular case report.
From October 2014 to August 2016, the patient
underwent 13 cycles q 5–12 weeks of PIPAC with cis-
platin 7.5 mg/m2 and doxorubicin 1.5 mg/m2 at 12
mmHg. PIPAC was performed as described before (5).
Briefly, both drugs were applied into the abdomen via
laparoscopy using a 12 mmHg CO2 pneumoperitoneum,
an aerosolizer (Capnopen®, Capnomed, Villingen,
Germany), and an intravenous high-pressure injector
(Arterion Mark 7, MedRad Bayer Healthcare, Berlin,
Germany). A video of a PIPAC application is available in
the (Additional file 1: Video S1) of the electronic version
of the manuscript. Adverse events were graded accord-
ing to the CTCAE version 4.0. Quality of life was mea-
sured by the standardized European Organization for
the Research and Treatment of Cancer (EORTC) QLQ-
C30, version 3.0, questionnaire, a validated tool for
assessing quality of life in cancer patients. Between Oc-
tober 2015 and May 2016, tamoxifen 20 mg once daily
was taken by the patient. In May 2016 intravenous car-
boplatin area under the curve (AUC) 3 was added on
day 2 after each PIPAC due to local progression diag-
nosed on a computed tomography scan.
Figure 1 shows screenshots of video-laparoscopies dur-
ing consecutive PIPACs demonstrating PC and response
to PIPAC, evidenced by fibrosis and reticular sclerosis of
PC nodules. Histological objective tumor response was
noted by grading of tumor cell regression. Figure 2 dem-
onstrates histopathological specimens of the initial
tumor specimen sampled during PIPAC #1 with periton-
eal manifestations of serous carcinoma with large, pleo-
morphic nuclei and frequent mitosis and histopathological
specimens taken during consecutive PIPACs with residual
peritoneal tumor foci with reduced cellularity and fibroe-
lastic connective tissue with inflammatory changes such
as fibrinous exudate, fibrosis, foreign-body reaction, and
hemosiderin-laden macrophages.
Intraoperative assessment of PCI during repeated
PIPACs confirmed stable disease. The PCI noted by
laparoscopy during the 13 PIPAC sessions was 25, 19,
10, 15, 15, 13, 14, 10, 8, 10, 15, 6, and 12. The treatment
was well tolerated. CTCAE events grade 1 (abdominal
pain, fever) were noted within 72 h after 7 PIPAC proce-
dures. A CTCAE event grade 3 was observed twice at the
time of PIPAC #11 and #12 (two episodes of symptomatic
pleural effusions necessitating pleural puncture and drain-
age). There was no acute or cumulative renal, hepatic, or
hematologic toxicity throughout the whole treatment
period. We observed stable or declining values of creatin-
ine, γGT, GOT/ASAT, GPT/ALAT, lactate dehydrogenase,
alkaline phosphatase, C-reactive protein, bilirubin, and
Quick throughout all PIPAC procedures (Fig. 3). Serum
levels of CA 125 fluctuated between 1273 and 3486 U/
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mL. Figure 4 shows EORTC QLQ-C30 quality of life
scores indicating a stabilization of the patient’s quality of
life during the treatment period. Specifically, scores for
pain, vomiting, and obstipation/diarrhea were stable
throughout the treatment, suggesting that intraabdominal
maintenance chemotherapy with PIPACs does not result
in acute or cumulative gastrointestinal toxicity.
Discussion
Women with primary advanced, unresectable OC are
confronted with a palliative situation, which is often
characterized by substantial co-morbidities and a low
quality of life [4, 15]. The standard of care for these
women is systemic polychemotherapy with or without
the addition of targeted therapies. The toxicity of these
Fig. 1 Intraoperative findings (macroscopy) during video-laparoscopy before the first (panels a–c), fourth (panel d), seventh (panel e), and twelfth
(panel f) pressurized intraperitoneal aerosol chemotherapy (PIPAC) application. During the course of therapy, sclerosis and flattening of peritoneal
nodules as well as reticular scarring of the visceral and parietal peritoneum were observed
Fig. 2 Intraoperative findings (microscopy) before the first pressurized intraperitoneal aerosol chemotherapy (PIPAC) (a), and during consecutive
PIPAC cycles (PIPAC #3 (b), PIPAC #5 (c), and PIPAC #6 (d). Panel A shows peritoneal manifestations of a serous carcinoma with large, pleomorphic
nuclei and frequent mitosis. Histopathological specimens taken during consecutive PIPACs 3, 5, and 6 (panels b, c, and d, respectively) show residual
peritoneal tumor foci with reduced cellularity and fibroelastic connective tissue and associated inflammatory changes such as fibrinous exudate,
fibrosis, foreign-body reaction, and hemosiderin-laden macrophages. Bars, 100 μm
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regimens, however, is substantial, making it difficult to
balance the advantages of the therapy and the toxicity
and loss of quality of life during the limited life expect-
ancy left for these patients. Thus, additional and less
toxic treatment options with minimal or no adverse ef-
fects on the quality of life are warranted and an unmet
medical need at present. Intraperitoneal chemotherapy
has been demonstrated to be effective in women with
OC in the adjuvant setting. PIPAC is a form of intraperi-
toneal chemotherapy with minimal systemic side effects,
using pressurized, aerosolized chemotherapy in order to
improve drug distribution and tumor penetration [12].
Preliminary data in patients with advanced PC demon-
strate good tolerability and objective tumor response
[12, 13]. PIPAC can be applied repeatedly without cumu-
lative toxicity and a low amount of systemic chemother-
apy burden. Previous studies have demonstrated that
PIPAC does not adversely affect quality of life [13, 14].
These properties make PIPAC a potential alternative to
systemic chemotherapy in women with primary ad-
vanced, unresectable OC.
We present the case of a 75 year old woman with
unresectable OC and the successful application of 13 cy-
cles of PIPAC as maintenance therapy over a period of
two years. Objective tumor response was noted, defined
as tumor regression on histology and video-laparoscopy.
Clinical assessments, serum CA 125 measurements, and
consecutive PCI values showed stable disease. Most
importantly, quality of life did not decline and was main-
tained at a high level throughout the therapy. This case
report suggests that PIPAC may be a reasonable alterna-
tive to systemic chemotherapy in selected women with
primary advanced, unresectable OC.
Besides ovarian cancer, PIPAC has been tested in other
peritoneal surface malignancies, e.g. gastric cancer [14],
colorectal cancer [16], pseudomyxoma peritonei [17],
Fig. 3 Scatter plots demonstrating serum levels of gamma glutamyl transferase (γGT), aspartate aminotransferase (GOT/ASAT), alanine
aminotransferase (GPT/ALAT), lactate (LDH), alkaline phosphatase (ALP), C-reactive protein (CRP), bilirubin, creatinine (CREA), hemoglobin
(Hb) and Quick values throughout 13 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures. Linear regression lines are
shown (solid. Pearson product moment correlation with p < 0.05; dotted, no correlation)
Tempfer et al. BMC Cancer  (2017) 17:26 Page 4 of 6
suggesting that this is an effective tool for the treatment
of various forms of PC using different drugs such as
oxaliplatin, cisplatin, and doxorubicin. The goold local
and systemic tolerability of PIPAC as suggested by
this case report and a series of other studies [12–14,
16, 17], indicates that more drugs and alternative
combinations of drugs should be tested via the PIPAC
approach.
QoL is a major treatment goal in oncology, especially
in palliative patients. Thus, we made efforts to document
eventual changes in QoL throughout the treatment using
a validated tool, i.e. the EORTC QLQ-C30 questionnaire.
The treatment was well tolerated and the QoL initially
improved during therapy with an intermittent decline
after 10 treatment courses. Cumulative hepatic or renal
toxicity was not observed. Also, gastrointestinal QoL
measures remained stable throughout all PIPAC courses,
which indicates that PIPAC, although repeatedly applied
directly into the abdomen, does not result in acute or
cumulative gastrointestinal toxicity.
It has to be stated, however, that this patient could
have also achieved stable disease with conventional
chemotherapy without the costs and burden of 13 serial
laparoscopies. Therefore, PIPAC may be an alternative
to systemic chemotherapy fpor patients refusing sys-
temic chemotherapy, but willing to undergo intraperito-
neal chemotherapy.
Conclusion
PIPAC is a new form of IPC, which can be applied repeat-
edly over a long period of time and with a minimal impact
on quality of life. PIPAC may be a reasonable alternative
to systemic chemotherapy in selected women with pri-
mary advanced, unresectable OC given that it preserves
quality of life and has minimal systemic side effects.
Fig. 4 European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 (version 3.0) scores. GHS/QL2, global health status/QoL (revised).
Functional scales: PF2, physical functioning (revised); RF2, role functioning (revised); EF, emotional functioning; CF, cognitive functioning; SF, social
functioning. Symptom scales/items: FA, fatigue; NV, nausea and vomiting; PA, pain; IN, insomnia; AL, appetite loss; CO, constipation; DI,
diarrhea; FD, financial difficulties. Diamonds represent consecutive pressurized intraperitoneal aerosol chemotherapies (PIPACs, cycles 1–13;
note: data for cycle 3 are missing)
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Additional file
Additional file 1: with a pressurized intraperitoneal aerosol
chemotherapy (PIPAC). A Supplementary Video (41 min) is available on
YouTube at: https://www.youtube.com/watch?v=YsRw7Z5ocLY. This
video shows the first application of a pressurized intraperitoneal aerosol
chemotherapy (PIPAC) performed in the patient described in this case
report. Ascites, peritoneal carcinomatosis, adhesions, and application of
aerosolized chemotherapy (doxorubicin and cisplatin) via a pressure
pump is demonstrated. (WEBM 148 MB)
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